期刊文献+

人巨细胞病毒感染对多种病毒感染的影响 被引量:3

原文传递
导出
摘要 人巨细胞病毒( human cytomegalovirus,HCMV)属β疱疹病毒亚科,人群对其普遍易感,成人HCMV感染率可达30%~100%[1].在机体免疫功能正常时,HCMV常呈隐性或潜伏感染,而在免疫功能低下或缺陷时(如移植受者、艾滋病患者等)常呈显性感染.HCMV感染后不仅可通过直接的致细胞病变作用,引起HCMV症状和侵入性疾病(如HCMV肺炎、肝炎、胃肠炎、脑炎等),还可通过间接的宿主依赖的免疫病理作用,引起移植排斥、移植物损伤,诱发机会性感染等[2].HCMV感染可诱导激活其他人疱疹病毒( human herpesviruses,HHV)的活动性感染,如HHV-6、HHV-7、EB病毒(EBV)等[2],而有关其对多瘤病毒[多瘤BK病毒(BK virus,BKV)、多瘤JC病毒(JC virus,JCV)、乙型肝炎病毒(hepatitis B virus,HBV)、丙型肝炎病毒(Hepatitis C virus,HCV)]机会性感染的影响研究甚少.因此,本研究通过比较肾移植患者HCMV感染组和非感染组移植术后HCMV、BKV、JCV、HBV、HCV感染率的差别,来初步探究HCMV感染对上述病毒机会性感染的影响.
出处 《中华检验医学杂志》 CAS CSCD 北大核心 2012年第1期59-61,共3页 Chinese Journal of Laboratory Medicine
基金 基金项目:浙江省医药卫生科学项目(2008A007)
  • 相关文献

参考文献1

二级参考文献92

  • 1Sarmiento JM,Dockrell DH,Schwab TR,et al.Mycophenolate mofetil increases cytomegalovirces invasive organ disease in renal transplant patients. Clinical Transplantation . 2000
  • 2Humar A,Snydman D.Cytomegalovirus in solid organ transplant recipients. American Journal of Transplantation . 2009
  • 3R R Razonable,A Rivero,A Rodriguez,et al.Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir. The Journal of Infectious Diseases . 2001
  • 4Razonable RR,Emery VC.Management of CMV infection and disease in transplant patients. 27-29 February 2004. Herpes . 2004
  • 5Razonable RR,,Paya CV.Herpesvirus infections in transplant recipients: current challenges in the clinical management of cytomegalovirus and Epstein-Barr virus infections. Herpes . 2003
  • 6Razonable RR,Paya CV.Infections and allograft rejection-intertwined complications of organ transplantation. Swiss Medical Weekly . 2005
  • 7Arthurs SK,Eid AJ,Pedersen RA,Kremers WK,Cosio FG,Patel R,Razonable RR.Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation. Clinical Infectious Diseases . 2008
  • 8Gane E,Saliba F,Valdecasas GJ,O’Grady J,Pescovitz MD,Lyman S,Robinson CA.Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients.The Oral Ganciclovir International Transplantation Study Group[corrected]. The Lancet . 1997
  • 9Fica A,Cervera C,Pérez N,Marcos MA,Ramírez J,Linares L,Soto G,Navasa M,Cofan F,Ricart MJ,Pérez-Villa F,Pu-marola T,Moreno A.Immunohistochemically proven cyto-megalovirus end-organ disease in solid organ transplant patients:clinical features and usefulness of conventional diagno stic tests. Transplant Infectious Disease . 2007
  • 10Razonable RR,van Cruijsen H,Brown RA,Wilson JA,Harmsen WS,Wiesner RH,Smith TF,Paya CV.Dynamics of cytomegalovirus replication during preemptive therapy with oral ganciclovir. The Journal of Infectious Diseases . 2003

共引文献5

同被引文献34

引证文献3

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部